期刊文献+

去势疗法与免疫疗法结合治疗前列腺癌的疗效及对IL-8、IL-6、TNF-α水平的影响

下载PDF
导出
摘要 目的分析前列腺癌患者采取去势疗法与免疫疗法结合治疗的疗效,评价对于白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平的影响。方法 92例前列腺癌患者,采取随机分组方法分为实验组和常规组,每组46例。常规组接受去势疗法治疗,实验组接受去势疗法与免疫疗法结合治疗。比较两组治疗效果及治疗前后免疫功能指标[免疫球蛋白M(IgM)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)]、炎症因子(IL-8、IL-6、TNF-α)、激素指标[血清前列腺特异性抗原(PSA)、血清睾酮(T)]水平。结果实验组治疗总有效率为97.83%,高于常规组的84.78%,差异具有统计学意义(P<0.05)。治疗后,实验组IgG水平高于常规组, IgA、IgM水平低于常规组,差异具有统计学意义(P<0.05)。治疗后,实验组IL-8、IL-6、TNF-α水平分别为(3.78±0.57)、(0.64±0.31)、(1.32±0.47)ng/ml,低于常规组的(10.72±2.15)、(0.84±0.42)、(3.57±0.74)ng/ml,差异具有统计学意义(P<0.05)。治疗后,实验组血清PSA、T水平低于常规组,差异具有统计学意义(P<0.05)。结论对于前列腺癌采取去势疗法与免疫疗法结合治疗效果显著,可有效改善免疫功能及炎症因子水平,对控制疾病具有重要意义,临床应用价值较高。
出处 《中国实用医药》 2021年第22期70-73,共4页 China Practical Medicine
  • 相关文献

参考文献6

二级参考文献49

  • 1Heidenreicb A, Aus G, Bolla M, et al. EAU guidelines on pros- tate cancer [J]. Eur Urol, 2008, 53: 68-80.
  • 2McMillan DC. Cancer and systemic inflammation: stage the tumour and stage the host [J]. Br J Cancer, 2013, 109: 529.
  • 3Linton A, Pond G, Clarke S, et al. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy [ J ]. Clin Genitourin Cancer, 2013, 11: 423-430.
  • 4Karan D, Lin MF, Johansson SL, et al. Current status of the mo- lecular genetics of human prostatic adenocarcinomas [ J ]. Int J Cancer, 2003, 103: 285-293.
  • 5Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific An- tigen Working Group [J]. J Clin Oncol, 1999, 17: 3461-3467.
  • 6Mantovani A, Allavena P, Sica A, et al. Cancer-related inflam- mation [J]. Nature, 2008, 454: 436-444.
  • 7Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? [J]. Lancet, 2001, 357: 539-545.
  • 8Chua W, Clarke SJ, Charles KA. Systemic inflammation and pre- diction of chemotherapy outcomes in patients receiving doeetaxel for advanced cancer [ J ]. Support Care Cancer, 2012, 20 : 1869- 1874.
  • 9De Wit R. Chemotherapy in hormone-refractory prostate cancer [J]. BJU Ira, 2008, 10l Suppl2: S11-15.
  • 10Miyake H, Sakai I, Terakawa T, et al. Oncological outcome of doeetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer [J]. Urol Oncol, 2013, 31: 733-738.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部